2015


To access this material please log in or register

Register Authorize
2015/№6

Survival of chronic heart failure patients with different time to the maximum response to cardiac resynchronization therapy

Kuznetsov V. A., Soldatova A. M., Krinochkin D. V., Enina T. N.
Branch of the Federal State Budgetary Science Institution, “Research Institute of Cardiology” at the Siberian Branch of the Russian Academy of Medical Sciences, “Tyumen Cardiology Center”, Melnikaite 111, Tyumen 625026

Keywords: prognosis, resynchronization therapy, CHF

DOI: 10.18087 / rhfj.2015.6.2141

Background. The experience of implanting resynchronizing devices has demonstrated that the response to cardiac resynchronizing therapy (CRT) and the time to the optimum response are rather individual. Data on correlation of the time to the optimum response with patient survival are not available. Aim. To identify clinical and morpho-functional features of CHF patients with different time to the optimum response to CRT and to evaluate patient survival in relation to the time to the maximum response. Material and methods. The study included 106 patients (males, 83 %) with NYHA FC II–IV CHF (mean age, 54.7±9.9). Clinical examination and EchoCG were performed at baseline, at 1 and 3 months, and then every 6 months. Mean follow-up duration was 34.9±16.1 months. Time of the greatest decrease in LV end-systolic volume (ESV) was considered the time to the optimum response to CRT. Patients with the time to the optimum response within the first three months after implantation were included into the first group (group I, fast peak response, n=26) and patients with the peak response after more than three months – into the second group (group II, delayed peak response, n=80). Results. The proportion of responders was significantly higher in group II than in group I (90 % vs. 61.5 %, р=0.001); furthermore, all patients with a more than 30 % decrease in LV ESV (superresponders) had a delayed maximum response. LV ESV was reduced and LV EF was increased in both groups; however, these changes were significantly more pronounced in patients of group II. Overall survival was 74.1 % in group I and 96.2 % in group II (log-rank test, p<0.001). According to results of the Cox regression analysis, both LV ESV (HR, 1.004; 95 % CI, 1.005–1.024; р=0.002) and time to the optimum response (HR, 5.677; 95 % CI, 1.332–24.193; р=0.019) significantly correlated with survival during the follow-up period. Conclusion. Patients with a delayed peak response better responded to CRT, which was evident as greater proportions of responders and superresponders in this group as well as better time-related changes in LV ESV and LV EF. Fast peak response to CRT and higher baseline values of LV ESV were associated with higher mortality in the remote follow-up period.
  1. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013 Aug;34 (29):2281–329.
  2. Бокерия Л. А, Бокерия О. Л., Глушко Л. А. Метаанализ современных клинических исследований и отдаленные результаты применения хронической ресинхронизирующей терапии. Анналы аритмологии. 2012;9 (1):44–55.
  3. Кузнецов В. А., Виноградова Т. О., Енина Т. Н., Колунин Г. В., Харац В. Е., Павлов А. В. и др. Влияние сердечной ресинхронизирующей терапии на выживаемость пациентов с кардиомиопатией ишемического и неишемического генеза в клинической практике. Терапевтический архив. 2012;84 (8):52–6.
  4. Кузнецов В. А, Мельников Н. Н., Криночкин Д. В., Колунин Г. В., Горбатенко Е. А. Острый гемодинамический эффект сердечной ресинхронизирующей терапии у пациентов с хронической сердечной недостаточностью. Вестник аритмологии. 2013;74:50–4.
  5. Ghio S, Freemantle N, Scelsi L, Serio A, Magrini G, Pasotti M et al. Long-term left ventricular reverse remodeling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail. 2009 May;11 (5):480–8.
  6. Prinzen FW, Auricchio A. The «missing» link between acute hemodynamic effect and clinical response. J Cardiovasc Transl Res. 2012 Apr;5 (2):188–95.
  7. Stellbrink C, Breithardt OA, Franke A, Sack S, Bakker P, Auricchio A et al. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. J Am Coll Cardiol. 2001 Dec;38 (7):1957–65.
  8. Mullens W, Verga T, Grimm RA, Starling RC, Wilkoff BL, Tang WH. Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol. 2009 Feb 17;53 (7):600–7.
  9. Кузнецов В. А. Сердечная ресинхронизирующая терапия: избранные вопросы. – М.: Абис, 2007. – 128с.
  10. Ревишвили А. Ш., Ардашев А. В., Бойцов С. А., Бокерия О. Л., Голухова Е. З., Давтян К. В. и др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Новая редакция. – М., 2013. – С. 96–127.
  11. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинникова А. Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению хронической сердечной недостаточности (четвертый пересмотр). Журнал Сердечная Недостаточность. 2013;14 (7):379–472.
  12. El Missiri A. M. Echocardiographic assessment of left ventricular mechanical dyssynchrony – A practical approach. The Egypt Heart J. 2014 Sep;66 (3):217–25.
  13. Cazeau SJ, Daubert JC, Tavazzi L, Frohlig G, Paul V. Responders to cardiac resynchronisation therapy with narrow or intermediate QRS complexes identified by simple echocardiographic indices of dyssynchrony: The DESIRE study. Eur J Heart Fail. 2008 Mar;10 (3):273–80.
  14. Auricchio A, Faletra FF. Mechanical dyssynchrony in CRT patients: still searching for the Holy Grail! Eur J Heart Fail. 2008 Mar;10 (3):217–9.
  15. Reant P, Zaroui A, Donal E, Mignot A, Bordachar P, Deplagne A et al. Identification and characterization of super-responders after cardiac resynchronization therapy. Am J Cardiol. 2010 May 1;105 (9):1327–35.
  16. Vaillant C, Martins RP, Donal E, Leclercq C, Thebault C, Behar N et al. Resolution of left bundle branch block-induced cardiomyopathy by cardiac resynchronization therapy. J Am Coll Cardiol. 2013 Mar 12;61 (10):1089–95.
  17. Mascioli G, Padeletti L, Sassone B, Zecchin M, Lucca E, Sacchi S et al. Electrocardiographic criteria of true left bundle branch block: a simple sign to predict a better clinical and instrumental response to CRT. Pacing Clin Electrophysiol. 2012 Aug;35 (8):927–34.
  18. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Daubert JC et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec;34 (46):3547–56.
  19. Inden Y, Ito R, Yoshida N, Kamiya H, Kitamura K, Kitamura T et al. Combined assessment of left ventricular dyssynchrony and contractility by speckled tracking strain imaging: a novel index for predicting responders to cardiac resynchronization therapy. Heart Rhythm. 2010 May;7 (5):655–61.
  20. Maréchaux S, Guiot A, Castel AL, Guyomar Y, Semichon M, Delelis F et al. Relationship between two-dimensional speckle-tracking septal strain and response to cardiac resynchronization therapy in patients with left ventricular dysfunction and left bundle branch block: a prospective pilot study. J Am Soc Echocardiogr. 2014 May;27 (5):501–11.
  21. Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: the magnitude of the problem and the issues. Circ J. 2011;75 (3):521–7.
  22. Steffel J, Ruschitzka F. Superresponse to cardiac resynchronization therapy. Circulation. 2014 Jul 1;130 (1):87–90.
  23. Cleland JG, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, Daubert JC. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail. 2012 Jun;14 (6):628–34.
  24. Cleland JG, Ghio S. The determinants of clinical outcome and clinical response to CRT are not the same. Heart Fail Rev. 2012 Nov;17 (6):755–66.
  25. Cleland JG. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients’ clinical journey. Eur J Heart Fail. 2002 Jun;4 (3):243–7.
  26. Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F et al. Management of heart failure in primary care (the IMPROVEMENT of heart failure programme): an international survey. Lancet. 2002 Nov 23;360 (9346):1631–9.
Kuznetsov V. A., Soldatova A. M., Krinochkin D. V., Enina T. N.Survival of chronic heart failure patients with different time to the maximum response to cardiac resynchronization therapy. Russian Heart Failure Journal. 2015;16 (6):339–343

To access this material please log in or register

Register Authorize
Ru En